Applications for Induced Pluripotent Stem Cells in Disease Modelling and Drug Development for Heart Diseases

Shu Nakao,1,2,3 Dai Ihara,1,2 Koji Hasegawa3 and Teruhisa Kawamura1,2,3

1. Department of Biomedical Sciences, College of Life Sciences, Ritsumeikan University, Kusatsu, Japan; 2. Global Innovation Research Organization, Ritsumeikan University, Kusatsu, Japan; 3. Division of Translational Research, Kyoto Medical Center, National Hospital Organization, Kyoto, Japan

Abstract
Induced pluripotent stem cells (iPSCs) are derived from reprogrammed somatic cells by the introduction of defined transcription factors. They are characterised by a capacity for self-renewal and pluripotency. Human (hi)PSCs are expected to be used extensively for disease modelling, drug screening and regenerative medicine. Obtaining cardiac tissue from patients with mutations for genetic studies and functional analyses is a highly invasive procedure. In contrast, disease-specific hiPSCs are derived from the somatic cells of patients with specific genetic mutations responsible for disease phenotypes. These disease-specific hiPSCs are a better tool for studies of the pathophysiology and cellular responses to therapeutic agents. This article focuses on the current understanding, limitations and future direction of disease-specific hiPSC-derived cardiomyocytes for further applications.

Keywords
Induced pluripotent stem cell, cardiomyocyte, genetic disease, drug screening, gene editing

Induced Pluripotent Stem Cells and Their Potential Applications
Induced pluripotent stem cells (iPSCs) are generated from somatic cells, such as skin fibroblasts, by ectopic expression of defined reprogramming factors. Within a few years of the first report of the generation of mouse iPSCs, several laboratories reportedly reproduced these cells using other cell types and species using similar approaches.1–4 This early attention on reproducible methods for the production of iPSCs from mammalian cells accelerated research into iPSC technology for clinical applications. iPSCs show unlimited proliferation capacity and pluripotency, as observed in embryonic stem cells (ESCs), and thus have significant advantages as a cell source for producing sufficient numbers of any cell type. In contrast with ESCs, human (hi) iPSCs can be established from differentiated cells without destroying human embryos, thereby overcoming related ethical issues. Thus, iPSCs have been extensively investigated worldwide for applications in disease modelling, drug screening and regenerative medicine (Figure 1).5,6

When hiPSCs are derived from patients with a genetic disease caused by a mutation, such patient-derived iPSCs are called disease-specific hiPSCs. As disease-specific hiPSCs contain the same genetic information as the patient, including mutations corresponding to the altered gene function,6,7 disease-specific hiPSCs could potentially be a powerful tool for modelling human disease. Particularly in cardiovascular research, obtaining a sufficient number of cardiomyocytes (CMs) from patients is challenging due to the highly invasive procedures required to extract them. Further, the low proliferation capacity of CMs limits researchers’ ability to maintain these cells in culture. Being able to generate iPSC-derived CMs (hiPSC-CMs) from a specific patient overcomes this problem, and enables identification of typical cellular responses to pathological stress and therapeutic agents because these cells potentially reflect the biological responses of an individual patient’s own CMs (Figure 1).

Recent genetic research has led to the identification of gene mutations responsible for hereditary heart diseases. Investigations into the pathophysiology of those inherited diseases often use animal models that partially mirror the disease conditions. However, animal studies are low throughput, time consuming and relatively expensive. Moreover, there are interspecies differences between humans and the experimental animals in terms of molecular and physiological properties (e.g. ion channel expression profile, heart rate), as well as in the cellular responses to pathological stress. Therefore, experimental results...
obtained from animal models do not perfectly recapitulate the conditions occurring in humans, and are less reliable for the purpose of extrapolation. In contrast, disease-specific hiPSCs could be a valuable tool in research on inherited diseases and for testing therapeutic agents. hiPSCs are created from somatic cells, which can be easily collected from accessible patient tissues, such as skin and blood. Owing to their self-renewal property, hiPSCs could be used to produce a sufficient number of specific cell types following appropriate differentiation methods for further experiments in vitro.

### Human Induced Pluripotent Stem Cells for Modelling Inherited Arrhythmias

Advances in cardiovascular research have increased our understanding of the molecular mechanisms underlying various genetic diseases. Comprehensive genetic studies have identified causal mutations responsible for phenotypes of inherited cardiovascular diseases such as long QT syndrome (LQTS), Brugada syndrome and cardiomyopathies.

LQTS is characterised by a significantly prolonged QT interval attributable to delayed repolarisation in the ventricular myocardium. Some types of LQTS cause life-threatening arrhythmias in response to stimuli such as swimming and sudden loud noise. Genetic studies have found a number of gene loci responsible for LQTS in families with a high incidence of the disease. Despite an absence of clinical symptoms under sedentary conditions in patients with LQTS, once ventricular tachyarrhythmias are triggered by specific stimuli, patients with LQTS are prone to exhibit syncope. Sustained arrhythmias ultimately lead to VF, resulting in sudden cardiac death. Several studies on patients with LQTS have identified a number of mutations in genes encoding cardiac ion channels, which are membrane proteins regulating the generation and propagation of action potential. However, these mutations are not always responsible for the observed symptoms, even when the patients are exposed to the stimuli that trigger electrophysiological changes.

Effects of the stimuli or therapeutic agents, as well as the incidence of cardiac events, vary considerably among individual patients. Therefore, to address issues related to proarrhythmic mechanisms in individuals with inherited LQTS, patient-derived hiPSC-CMs with the corresponding mutation(s) could serve as powerful tools for in vitro experiments. Previous studies characterising mutations of the alpha-subunit of the potassium voltage-gated channel subfamily Q member 1 ( KCNQ1, also known as K,QT1 and K,7.1) using patient-derived iPSC-CMs revealed that impaired membrane trafficking of Ks channels and reduced delayed rectifier potassium channel current (I) cause LQT1. Izhaki et al. introduced reprogramming factors into dermal fibroblasts obtained from patients with a mutation in the alpha-subunit of potassium voltage-gated channel subfamily H member 2 ( KCNHN), responsible for (I) causing LQT2. Spontaneously beating hiPSC-CMs carrying this mutation were used for functional analysis and exhibited a prolonged QT interval similar to that in LQTS patients.

Similar studies using hiPSC-CMs derived from a patient with a missense mutation in KCNHN also exhibited action potential prolongation, smaller (I) early afterdepolarisations and arrhythmias. These changes were recovered or exaggerated by pharmacological agents or selective RNA interference in disease-specific hiPSC-CMs.

Disease-specific hiPSC-CMs from patients and families with Timothy syndrome (LQT8) that have a mutation located in calcium voltage-gated channel subunit alpha 1C (CACNA1C, responsible for the L-type calcium current, (I)) have been established and assessed for mutation-associated phenotypes in vitro and in vivo. An LQT8 model using patient-specific hiPSC-CMs reflected cellular electrical abnormalities, including prolonged action potential duration, delayed afterdepolarisations and altered Ca⁺⁺ transients. In contrast, roscovitine, an inhibitor of cyclin-dependent kinase 5, a key mediator involved in the regulation of Ca⁺⁺1.2 channels, enhanced (I), inactivation, shortened action potential duration, restored the irregular Ca⁺⁺ transient and decreased the frequency of abnormal depolarisations in LQT8 hiPSC-CMs.

Furthermore, other inherited arrhythmias have been investigated using disease-specific hiPSC-CMs, including various types of LQTS – mutations in sodium voltage-gated channel alpha subunit 5 ( SCN5A), potassium inwardly rectifying channel subfamily J member 2 ( KCNJ2), coactivator 1 ( CALM1) or calmodulin 2 ( CALM2), short QT syndrome ( KCNHN2 mutation), Brugada syndrome type 1 ( SCN5A mutation) and catecholaminergic polymorphic ventricular tachycardia (mutations in ryanodine receptor 2 ( RYR2) or calsequestrin 2 ( CASQ2)). These cells recapitulated cellular electrophysiological changes in the heart of patients. Table 1 summarises the different studies that have used hiPSC-CMs as models to investigate inherited arrhythmias.

### Human Induced Pluripotent Stem Cells for Modelling of Inherited Cardiomyopathies

In addition to inherited arrhythmias, there are some incidences of cardiomyopathies in families carrying specific genetic variant(s) that are responsible for causing the disease. Dilated cardiomyopathy (DCM) is a major type of cardiomyopathy that is characterised by systolic dysfunction and dilated cardiac chambers comprised of thin myocardial walls. Most cases of DCM without any identifiable cause (e.g. coronary artery disease, systemic hypertension, viral infection) are diagnosed as "idiopathic" DCM.

Based on family history and clinical findings, including sudden cardiac death, heart failure and abnormal echocardiography, previous clinical studies have proposed that familial transmission of idiopathic DCM is...
| Disease Phenotype | Causal Genes | Cellular Phenotypes in iPSC-CMs | Drug Responses |
|-------------------|-------------|--------------------------------|----------------|
| LQT1 (Andersen–Tawil syndrome) | KCNQ1 (R190Q) | Reduced drug-induced FPD, APD prolongation, EADs, triggered activity | Reduced |
| LQT2 (Benson type II) | KCNQ1 (G406R) | Reduced APD, delayed repolarisation, EADs | Reduced, increased |
| LQT3 (Overlap syndrome) | KCNQ1 (V1763M) | Increased APD, EADs | Reduced |
| LQT4 (Jervell–Lange-Nielsen syndrome) | KCNQ1 (R218W, R67W, R67Q, R67H) | Reduced APD, EADs | Reduced |
| LQT5 (Mutations) | KCNQ1 (exon 7 deletion) | Reduced drug-induced FPD, APD prolongation, EADs, triggered activity | Reduced |
| LQT6 (Lehmann–Nordahl syndrome) | KCNQ1 (F1473C) | Reduced APD, EADs | Reduced |
| LQT7 (Andersen–Tawil syndrome) | KCNQ1 (G1681A) | Reduced drug-induced FPD, APD prolongation, EADs, triggered activity | Reduced |
| LQT8 (Timothy syndrome) | KCNQ1 (N006I) | Reduced drug-induced FPD, APD prolongation, EADs, triggered activity | Reduced |
| LQT9 (Increased sensitivity to drugs) | KCNQ1 (R594Q, R190Q) | Reduced drug-induced FPD, APD prolongation, EADs, triggered activity | Reduced |
| LQT10 (Jervell–Lange-Nielsen syndrome) | KCNQ1 (F1473C) | Reduced APD, EADs | Reduced |
| LQT11 (Jervell–Lange-Nielsen syndrome) | KCNQ1 (G406R) | Reduced APD, EADs | Reduced |
| LQT12 (Increased sensitivity to drugs) | KCNQ1 (N006I) | Reduced drug-induced FPD, APD prolongation, EADs, triggered activity | Reduced |

Table 1: Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Models of Inherited Arrhythmias
### Table 1: Cont.

| Disease          | Disease Phenotype                                             | Causal Genes (Mutations) | Cellular Phenotypes in iPSC-CMs                                                                 | Drug Responses                                                                 | References             |
|------------------|----------------------------------------------------------------|--------------------------|-------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------|------------------------|
| Short QT syndrome| Shortened QT, sudden cardiac death                            | KCNH2 (N588K)            | Increased KCNH2 expression, increased If density, shortened APD, irregular and abnormal Ca^{2+} transients, arrhythmic activity induced by carbachol (cholinergic activator) | Quinidine (multiple channel inhibitor) prolonged APD and carbachol-induced arrhythmias | B-Battawry et al.28    |
|                  |                                                                |                          |                                                                                                 |                                                                               |                        |
| Brugada syndrome 1| Coved-type ST elevation followed by a descending negative T wave in V1 to V3 on ECG, risk of malignant ventricular arrhythmias, reduced Na^{+} current | PKP2 (c.2484C>T)         | Reduced If density, restored by wild-type gene expression                                        | N/A                                                                          | Cerrone et al.29       |
|                  |                                                                |                          |                                                                                                 |                                                                               |                        |
|                  |                                                                | SCN5A (R620H, R811H)     | Increased If density and maximal upstroke AP velocity, abnormal Ca^{2+} transients, variable beating intervals | N/A                                                                          | Liang et al.20         |
|                  |                                                                |                          |                                                                                                 |                                                                               |                        |
|                  |                                                                | SCN5A (R367H)            | Reduced If density                                                                               | N/A                                                                          | Selga et al.31         |
| CPVT1            | Stress-induced ventricular tachyarrhythmias in structurally normal hearts | RYR2 (F2483I)            | DADs, altered and irregular Ca^{2+} transients, abnormal Ca^{2+} response after cAMP-induced phosphorylation | DADs were induced by isoproterenol. Abnormal Ca^{2+} response after repolarisation was abolished by forskolin (adenylyl cyclase agonist) | Fatima et al.32        |
|                  |                                                                |                          |                                                                                                 |                                                                               |                        |
|                  |                                                                | RYR2 (M4109R)            | Isoproterenol or forskolin (adrenergic stimulation)-enhanced DADs and triggered activity, EADs, irregular Ca^{2+} transients | DADs were eliminated by flecainide (Na^{+} blocker) and thapsigargin (SERCA inhibitor) | Itzhaki et al.33       |
|                  |                                                                |                          |                                                                                                 |                                                                               |                        |
|                  |                                                                | RYR2 (S406L)             | Isoproterenol-induced diastolic Ca^{2+} elevation, reduced SR Ca^{2+} content, DADs, increased frequency and duration of Ca^{2+} release, arrhythmias | Dantrolene (RyR inhibitor) restored normal Ca^{2+} spark properties and rescued the arrhythmogenic phenotype | Jung et al.24, 25      |
|                  |                                                                |                          |                                                                                                 |                                                                               |                        |
|                  |                                                                | RYR2 (P2328S)            | Abnormal Ca^{2+} transients, EADs, reduced SR Ca^{2+} content, increased non-alternating variability of Ca^{2+} transients in response to isoproterenol and adrenaline, decreased AP upstroke velocity | N/A                                                                           | Jung et al.34, 35, 36  |
|                  |                                                                |                          |                                                                                                 |                                                                               |                        |
|                  |                                                                | RYR2 (R420Q)             | Less developed ultrastructure, isoproterenol-induced arrhythmias and increased diastolic Ca^{2+} levels | N/A                                                                           | Novak et al.37         |
|                  |                                                                |                          |                                                                                                 |                                                                               |                        |
|                  |                                                                | RYR2 (L3741P)            | Altered Ca^{2+} transients, low SR Ca^{2+} content, Ca^{2+} leak, isoproterenol-induced irregular Ca^{2+} waves, prolonged Ca^{2+} sparks and DADs | Cellular phenotype was rescued by flecainide (Na^{+} blocker)                  | Preininger et al.38    |
|                  |                                                                |                          |                                                                                                 |                                                                               |                        |
|                  |                                                                | RYR2 (4587V)             | Increased diastolic Ca^{2+} waves, pacing-induced DADs                                          | S107 (RYR2 stabiliser) reduced DADs                                           | Sasaki et al.40        |
| CPVT2            | Stress-induced ventricular tachyarrhythmias in structurally normal hearts | CASQ2 (D307H)           | Isoproterenol-induced DADs, EADs, oscillatory arrhythmic prepotentials, increased diastolic intracellular Ca^{2+} levels, irregular Ca^{2+} transients, reduced threshold for store overload-induced Ca^{2+} release, myofibril disorganisation, SR abnormalities, reduced caveolae | Propranolol, carvedilol (beta-blockers), niluzole and flecainide (Na^{+} blockers) inhibited isoproterenol-induced arrhythmia | Jung et al.34, 35, 36  |
|                  |                                                                |                          |                                                                                                 |                                                                               |                        |

**Abbreviations:** AP = action potential; APD = action potential duration; CACNA1C = calcium voltage-gated channel subunit alpha1 C; CALM1 = calmodulin 1; CALM2 = calmodulin 2; CAMP = cyclic adenosine monophosphate; CASQ2 = calsequestrin 2; CDK5 = cyclin-dependent kinase 5; CM = cardiomyocyte; CPVT = catecholaminergic polymorphic ventricular tachycardia; DAD = delayed afterdepolarisation; EAD = early afterdepolarisation; EPP = field potential duration; ERP = pore-forming subunit of rapidly activating delayed rectifier potassium channel; iPSC-CM = induced pluripotent stem cell-derived cardiomyocyte; (F) = voltage-gated F-type calcium channel current; If = rapid delayed rectifier potassium current; If (= &lt;If = slow delayed rectifier potassium current; If = sodium current; If = late sodium current; If = sodium-calcium exchanger current; KCNH2 = potassium voltage-gated channel subunit H member 2; KCNQ1 = potassium voltage-gated channel subunit Q member 1; Kv = voltage-gated potassium channel; LQT = long QT; N/A = not applicable; Na = voltage-gated sodium channel; PKP2 = pleckstrin 2; RYR2 = ryanodine receptor 2; SERCA = sarcoplasmic/endoplasmic reticulum calcium ATPase; SR = sarcoplasmic reticulum.
observed in 20–50% of patients.42–44 When idiopathic DCM is identified in two or more family members, it is defined as familial DCM (FDC). FDC is largely caused by autosomal dominant mutations in key cardiac genes encoding sarcomere-related proteins, cytoskeletal proteins, mitochondrial proteins, nuclear membrane proteins and calcium regulators.43,45,46 These loss-of-function mutations lead to the abnormal morphology and function of the heart that is seen in idiopathic DCM. Moreover, recently developed high-throughput gene analyses have revealed that inherited DCM is associated with mutations in more than 100 gene loci.47

Although the pathophysiology of FDC is heterogeneous, the effect of each individual mutation has been unclear in the context of FDC. To address this, human CMs are ideal for in vitro functional analysis of mutations associated with FDC, but, as mentioned earlier, it is difficult to acquire a renewable source of cardiac cells. Compared with animal models and non-CMs expressing DCM mutant proteins, hiPSC-CMs are expected to exhibit responses similar to those observed in native human myocardium. For example, individual families carry a mutation that causes an arginine-to-tryptophan substitution at amino acid position 173 in the cardiac troponin T (cTnT) protein.48 Patient-specific hiPSCs were produced using minimally invasive procedures from skin fibroblasts of family members, and hiPSC-CMs were generated and tested to investigate the mechanisms underlying FDC. The FDC hiPSC-CMs exhibited reduced Ca$$^{2+}$$ influx and contractility, despite enhanced electrophysiological properties. These cells also showed the characteristic patchy structure of myofilaments, which was enhanced upon noradrenaline stimulation and stretching, leading to systolic dysfunction.48

This is consistent with the fact that the tendency towards DCM is enhanced by increases in inotropic effects and hypertension. These findings explain the involvement of cTnT dysfunction in the development of DCM. Thus, FDC hiPSC-CMs recreate, at least in part, the pathophysiology of DCM in human patients. Other causal gene mutations responsible for inherited cardiomyopathies, including DCM, hypertrophic cardiomyopathy and arrhythmogenic right ventricular cardiomyopathy/dysplasia, have been reported.49–57 Table 2 lists studies that have used hiPSC-CMs as models for investigating inherited cardiomyopathies.

Although numerous studies have summarised the characteristic features of familial heart diseases using patient-specific hiPSC-CMs, as described above, it is still challenging to fully recapitulate the disease phenotype using iPSC-CM-based disease modelling, primarily because hiPSC-CMs exhibit immature functions and morphology. For example, an incomplete ion channel profile (e.g. lack of $$I_{Na}$$, corresponding to slower action potential kinetics and a relatively positive diastolic potential) and subcellular structure (e.g. the absence of or underdeveloped T-tubule and sarcomere formation) are commonly observed in hiPSC-CMs.58–60 The gene expression profile of hiPSC-CMs also resembles that of foetal CMs and is distinct from that of adult CMs.60,61 The immaturity of hiPSC-CMs in terms of function and gene expression profile may result in controversial findings, particularly in the investigation of late-onset cardiac diseases that largely require adult CM-like cells for disease modelling.

In an in vitro study using hiPSC-CMs to investigate the pathophysiology of late-onset Pompe disease, which is characterised by slow progression of muscle weakness, although patient-specific hiPSC-CMs exhibited typical features associated with the disease, such as intracellular glycogen accumulation and mitochondrial dysfunction, they did not fully exhibit the autophagic abnormalities that are observed in vivo.62,63 This may be overcome by using fully differentiated hiPSC-CMs assembled along with a complete subcellular system for muscle contraction, Ca$$^{2+}$$ cycling, metabolism and protein recycling. Recent studies have contributed to the development of protocols for the maturation of hiPSC-CMs using electrical and/or mechanical stimulation, a 3D culture system with scaffold materials, coculture with fibroblasts or CMs in vitro and in vivo and a combination of these techniques, leading to improvement in contractility, Ca$$^{2+}$$ handling and electrophysiological properties.64–68

Lack of chamber-specific characteristics is another major concern regarding the use of hiPSC-CMs for disease modelling. As the structure, haemodynamic stress, developmental origin and protein expression profile are quite distinctive among the cardiac chambers,59,69,70 the molecular features of individual CMs in each chamber would also differ. Some inherited arrhythmias and cardiomyopathies have chamber-specific characteristics. Clinical phenotypes of Brugada syndrome and ARVC/D likely originate from the right ventricular outflow tract. However, disease models based on hiPSC-CMs may not fully recapitulate the characteristic features of any specific region of the heart.

A differentiated hiPSC-CM cluster usually consists of electrophysiologically heterogeneous subtypes including ventricular-, atrial- and nodal-like myocytes. The ventricular-like hiPSC-CMs exhibit properties analogous to those of human ventricular myocytes (e.g. steep upstroke (Phase 0) and plateau phase (Phase 4) of action potentials), whereas the nodal-type hiPSC-CMs exhibit slower action potential kinetics and depolarising diastolic potential.71 This mixed subtype of hiPSC-CMs leads to a wide range of results rather than being representative of a specific subtype of CMs. The development of protocols for subtype-specific and/or chamber-specific differentiation of hiPSC-CMs will accelerate research to identify the chamber-specific phenotypes associated with heart diseases. Although some genetic heart diseases are rare, many of them lead to life-threatening conditions. Therefore, further intensive research using disease-specific hiPSC-CMs should be promoted to gain insights into the underlying mechanisms and to identify potential therapeutic targets of these genetic diseases in order to develop novel therapeutic approaches for individual patients.

**Human Induced Pluripotent Stem Cells as a Tool for Drug Screening**

Currently, the development of new drugs requires multiple processes, including screening of numerous putative drug compounds based on chemical structure and in vitro assays of pharmacological activity, followed by analyses of pharmacokinetics and safety in vitro and in vivo and, finally, clinical trials in humans. In most cases, these processes take many years until the candidate compounds are tested in humans.72 Even though the effectiveness of compounds may be promising in cell culture and animal experiments, problems identified in clinical trials assessing the effects of these compounds on the QT interval (known as a thorough QT/QTc study) following pharmacokinetics examination in humans may halt the further development of these compounds. However, if human cardiac cells were widely available, drug testing in human CMs might provide effective and safe drug candidates rapidly and economically, because the response to compounds tested using in vitro experiments with human CMs could resemble that of the human body.
| Disease            | Disease phenotype                                                                 | Causal genes (mutations) | Cellular phenotypes                                                                                                                                  | Drug responses                                                                 | References               |
|--------------------|-----------------------------------------------------------------------------------|--------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------|--------------------------|
| DCM                | Dilation and impaired contraction of LV or both ventricles presenting various arrhythmias, leading to sudden death | TNNT2 (R173M)            | Reduced contraction force, compromised contraction, sarcomeric structural irregularities, reduced beating rate, abnormal Ca²⁺ transients, abnormal sarcomeric alpha-actinin distribution | Metoprolol (beta-blocker) improved abnormal functions                        | Grunig et al.⁴⁴         |
|                   | DES (A285V)                                                                      |                          | Diffuse abnormal desmin aggregations, diminished Ca²⁺ reuptake, reduced beating rate, failed sustained response to isoproterenol                     | N/A                                                                          | Morita et al.⁴⁵          |
| HCM                | Thickened LV causing diastolic dysfunction                                         | MYH7 (R663H)             | hPSC-CM hypertrophy, elevated intracellular Ca²⁺ levels, irregular Ca²⁺ transients                                                                  | Myocyte hypertrophy, Ca²⁺ handling abnormalities and arrhythmia were rescued by verapamil and diltiazem (Ca²⁺ blockers) | Sun et al.⁶⁸             |
|                   | LMNA (R225X, Q354X, T518fs, c.50-51insGCCA)                                      |                          | Nuclear bleb formation, microneedleation, nuclear senescence, electrical stimulation-induced cellular apoptosis | U0126 and selumetinib (AZD6244; ERK1/2 and MEK1/2 inhibitors) attenuated electric stimulation-induced proapoptotic effects | Tse et al., Carvajal-Vergara et al.⁵⁰ |
| HCM (Leopard syndrome) | Inherited disease characterised by skin, facial and cardiac anomalies             | PTPN11 (T426M)           | CM hypertrophy, NFATC4 nuclear accumulation, increased Ras/MAPK phosphorylation                                                 | N/A                                                                          | Mestroni et al.⁴⁶        |
| HCM (Pompe disease) | Hypotonia and signs of heart failure by the age of 3–5 months; accumulation of membrane-bound and cytoplasmic glycolgen and rupture of lysosomes, aberrant mitochondria, accumulation of autophagic vesicles leading to cardiomyopathy | GAA (C1935A/C1935A, C1935A/G2040+1T, G1062G/C1935A) | Glycogen accumulation, abnormal mitochondria ultrastructure, accumulation of autophagosomes, cellular respiration irregularities | rhGAA enzyme and 2-3-methyladenine (autophagy inhibitor) normalised glycogen content; 3-O-carnitine increased O₂ consumption and suppressed mitochondrial structural phenotype | Dellefave et al.⁵⁷ |
| ARVC/D             | Desmosomal dysfunction; ventricular arrhythmias; fatty or fibrofatty replacement of myocardium with thinning of the RV wall | PKP2 (c.972insT/N, A324fs335X) | Reduced density of PKP2, plakoglobin and connexin-43, FPD prolongation, widened and distorted desmosomes, lipid droplet clusters, increased lipid content in adipogenic differentiation media | Lipid accumulation was prevented by 6-bromoindirubin-3¢-oxime (glycogen synthase kinase-3-beta inhibitor) | Huang et al.⁵¹           |
|                   | PKP2 (c.2484C>T, c.2013delC)                                                     |                          | Irregular PKP2 nuclear accumulation, diminished beta-catenin activity in cardiogenic conditions, abnormal PPAR-gamma activation, Ca²⁺ handling defects | N/A                                                                          | Lan et al.⁵²             |
|                   | PKP2 (0:6,14P)                                                                   |                          | Reduced expression of PKP2 and plakoglobin, disorganised myofibrils, increased lipid content in adipogenic differentiation media                  | N/A                                                                          | Lee et al.⁵³             |

**Notes:**
- DCM = dilated cardiomyopathy
- DES = desmin
- ERK = extracellular signal-regulated kinase
- FPD = field potential duration
- GAA = acid alpha-glucosidase
- HCM = hypertrophic cardiomyopathy
- hPSC-CM = human induced pluripotent stem cell-derived cardiomyocyte
- LMNA = lamin A/C
- LV = left ventricle
- MAPK = mitogen-activated protein kinase
- MEK = mitogen-activated protein kinase kinase
- MYH7 = myosin heavy chain 7
- NFATC4 = nuclear factor of activated T cells cytoplasmic 4
- PKP2 = plakophilin 2
- PPAR-gamma = peroxisome proliferator-activated receptor-gamma
- PTPN11 = protein tyrosine phosphatase non-receptor type 11
- rh = recombinant human
- RV = right ventricle
- TNNT2 = troponin T2

**References:**
- Grunig et al.⁴⁴
- Morita et al.⁴⁵
- Sun et al.⁶⁸
- Tse et al., Carvajal-Vergara et al.⁵⁰
- Mestroni et al.⁴⁶
- Dellefave et al.⁵⁷
- Huang et al.⁵¹
- Lan et al.⁵²
- Lee et al.⁵³
Disease-specific hiPSC-derived CMs potentially exhibit similar physiological characteristics as diseased cells in patients, and may be a useful tool to predict the benefits and side-effects of drug candidates in patients. Drug screening using hiPSC-CMs to detect side effects such as drug-induced QT prolongation and ventricular tachyarrhythmias could contribute to the early withdrawal of therapeutic compounds with undesirable cardiac effects before the initiation of in vivo experiments and clinical trials. Other than the development of new drugs, the cardiac side effects of some already marketed drugs, including anti-arrhythmic drugs and non-cardiac drugs such as antihistamines, antipsychotics and anti-infective drugs, have been widely recognised. These drugs have the potential to cause torsade de points, in combination with other endogenous and environmental factors. Drug testing using hiPSC-CMs may also be applicable in this context.

Although hiPSC-CMs share some characteristics with adult human ventricular myocytes, hiPSC-CMs are commonly known to exhibit the features of foetal ‘immature’ CMs in terms of their gene expression profile, structure and electrophysiology, as noted above. hiPSC-CMs express cardiac-specific genes (e.g. those encoding cTnT, alpha-myosin heavy chain) and exhibit ion channel activity (e.g. similar $I_{Na}$, $I_{K}$ and $I_{Ca}$ current density to that in adult ventricular CMs); however, morphologically they are more rounded or multangular in shape and smaller in size, with disorganised myofibrils and a lack of t-tubules, which contribute to the slower kinetics of the Ca$^{2+}$ transient. These important differences should be considered when using hiPSC-CMs in drug screening. Further investigations are needed to develop optimal methods for more efficient differentiation into functional CMs that exhibit the typical properties of adult CMs.

Gene Editing to Create Disease-Specific Human Induced Pluripotent Stem Cells

Comprehensive genetic studies have identified causal mutations responsible for genetic heart diseases. hiPSC-CMs have emerged as a highly effective tool for modelling such diseases. Although it is technically possible to induce disease-specific hiPSC-CMs, patient-derived somatic cells may not be readily available, especially in the case of rare diseases. In addition, interclonal variation is seen among hiPSC clones, resulting from different genetic backgrounds associated with individual cells.

Clustered regularly interspaced short palindromic repeat (CRISPR)/CRISPR-associated protein (Cas) 9 is a gene-editing technology that can solve the challenges associated with the genetic variability. CRISPR is a DNA sequence found in bacterial genomes; it is thought to be derived from viruses, is known to protect bacteria from repeated viral infections and acts as a basic adaptive immune system for prokaryotes. Cas9 is a DNA-cutting enzyme that recognises CRISPR sequences and causes site-specific DNA double-strand breaks (Figure 2). Recent advances in CRISPR/Cas9-based gene editing have markedly improved the efficiency and specificity of the method and expanded its applications, including knockout, repression and activation of genes of interest.

In phenotypic analysis of monogenic inherited diseases, this technology is also applicable to either disease-associated mutagenesis in wild-type hiPSCs or to the correction of pathogenic gene mutations in disease-specific hiPSCs (Figure 3). Analysis of disease-specific hiPSCs versus wild-type hiPSCs established from healthy donor cells as a control may result in unreliable outcomes due to the different genetic backgrounds of the disease-specific hiPSCs and control cells. However, CRISPR/Cas9-based gene editing enables the preparation of an isogenic control by normalising a disease-relevant mutation in disease-specific hiPSCs or by inducing the mutation in wild-type hiPSCs so that diseased
and control cells with the same genetic background are obtained. In addition, CRISPR/Cas9-based gene editing could allow the production of isogenic cells with intact and/or corrected variant alleles in non-coding regions including enhancers that may reveal the role of mutations in the transcriptional regulation of genes responsible for a disease phenotype. This method shows promise for the proper evaluation of the involvement of mutated genes in disease phenotype following in vitro differentiation (Figure 3).

Polygenic diseases, which differ from monogenic inherited diseases in that more than one gene is involved in their dysfunction, impose another limitation on the use of hiPSCs. Polygenic diseases are thought to be caused by a combination of multiple mutations, each of which has a small effect, with or without extrinsic factors. Although gene editing has been used to edit multiple regions of the genome, a major challenge towards using hiPSCs to investigate polygenic diseases is identification of the corresponding mutations and understanding how each mutation contributes to the pathogenesis of these multifactorial diseases. Moreover, in some cases, environmental factors may strongly affect disease phenotypes, making experimental conditions and further analysis more complicated. Comprehensive reviews are available for detailed information regarding the use of gene editing in iPSC research. 89,91

Consideration of Human Induced Pluripotent Stem Cells for Application in Disease Modelling and Clinical Use

Despite extensive benefits, there are still many unsolved issues regarding the use of hiPSCs in further applications. One of the major issues is that the quality of individual hiPSC lines is variable, even when an hiPSC line is derived from one individual. Classical iPSC reprogramming methods using retroviral or lentiviral vectors may cause random insertion mutations in the host genome, resulting in alteration of subsequent cell phenotypes. 92

Recent advances in reprogramming strategies using non-integrating, virus-free and vector-free methods are overcoming this issue. 93,94 However, it is still technically difficult to eliminate the risk of gene mutations during the reprogramming process because forced expression of reprogramming factors can induce DNA damage. 95 In fact, protein-coding point mutations acquired during or after reprogramming were identified in multiple hiPSC lines, some of which exhibit unpredictable phenotypes. 96 Thus, accumulating evidence regarding the mechanism underlying the reprogramming of iPSCs is expected to provide insights into how the quality of hiPSC lines may be stabilised and standardised for use as a cell source for further experiments and clinical application.

Precise investigations into the pathophysiology of inherited diseases using patient-derived iPSCs require improved protocols that allow highly efficient differentiation of hiPSCs into a specific cell type, because the differentiation efficiency in current experiments remains significantly lower than what is desired. The characteristic variability of cells differentiated from disease-specific hiPSCs is a considerable hurdle that research into pathophysiology must overcome. Epigenetic modifications are presumably one of the causes of phenotype variability. Optimised sorting methods to collect only a desired cell type from the heterogeneous cell population need to be developed. Current research efforts are advancing cardiac differentiation protocols to generate spontaneously beating CM-like cell clusters, but the clusters of differentiated cells that are heterogeneous also contain other mesodermal derivatives, such as smooth muscle cells and endothelial cells, as well as undifferentiated cells, which may increase the risk of tumourigenesis.

Pathophysiological studies using disease-specific hiPSCs allow us to determine the cellular characteristics of a disease, but do not recreate the function of the whole organ within the body. Although complex bioengineering approaches, such as organoid formation and 3D culture systems, are available, it is difficult to use these methods in the heart because CMs in the heart are predominantly situated in a highly organised structure comprising vessels, nerves, mesenchymal cells, extracellular matrix and myocytes. In addition, CMs are continuously exposed to dynamically changing neuroendocrine factors and mechanical stresses. Therefore, it should be considered that studies using disease-specific hiPSC-CMs fundamentally provide simplified information regarding the pathophysiology in patients with a familial disease. Nevertheless, the experimental data from these cells may reveal responses that mirror actual phenomena in human patients, and are thus valuable for gaining an understanding of the inherited disease.

Conclusion

Disease-specific hiPSC-CMs, which carry the same genomic information as patients with inherited diseases, can undoubtedly be of use in research to address the pathophysiology of monogenic inherited diseases, the drug responsiveness of patients for personalised medicine and drug development by providing a cell source for screening compounds and drug safety testing. A combination of disease-specific hiPSC-CMs and gene-editing technologies may further advance our understanding of genetic diseases and drug development in cardiovascular medicine.

1. Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007;131:861–72. https://doi.org/10.1016/j.cell.2007.11.019; PMID: 18035408.
2. Takahashi K, Yamamura S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006;126:663–76. https://doi.org/10.1016/j.cell.2006.07.024; PMID: 16904174.
3. Yu J, Vodyanik MA, Smuga-Otto K, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007;318:1917–20. https://doi.org/10.1126/science.1151526; PMID: 18309452.
4. Park IH, Zhao R, West JA, et al. Reprogramming of human somatic cells to pluripotency with defined factors. Nature 2008;451:141–4. https://doi.org/10.1038/nature06343; PMID: 18107119.
5. Takahashi K, Yamamura S. A decade of transcription factor-mediated reprogramming to pluripotency. Nat Rev Mol Cell Biol 2016;17:183–93. https://doi.org/10.1038/nrm.2016.8; PMID: 26838003.
6. Muller R, Lengerke C. Patient-specific pluripotent stem cells: promises and challenges. Nat Rev Endocrinol 2009;5:195–203. https://doi.org/10.1038/nrendo.2009.18; PMID: 19332317.
7. Siller R, Greenough S, Park K, Sullivan GI. Modelling human disease with pluripotent stem cells. Curr Gene Ther 2015;13:99–110. https://doi.org/10.2174/156652321131502004; PMID: 23444871.
8. Matsui E, Rajamohan D, Dick E, et al. Drug evaluation in cardiomyocytes derived from human induced pluripotent stem cells carrying a long QT syndrome type 2 mutation. Eur Heart J 2011;32:592–622. https://doi.org/10.1093/eurheartj/eht072; PMID: 21367833.
9. Moretti A, Bellin M, Welling A, et al. Patient-specific induced pluripotent stem-cell models for long-QT syndrome. N Engl J Med 2010;363:1397–409. https://doi.org/10.1056/NEJMa0906879; PMID: 20642994.
10. Vezzosi M, Hussain I, Ia Ia, et al. Using induced pluripotent stem cells to investigate cardiac phenotypes in Timothy syndrome. Nature 2011;471:230–4. https://doi.org/10.1038/nature10985; PMID: 21307859.
11. Egashira T, Yusa S, Suzuki T, et al. Disease characterization using LQTS-specific induced pluripotent stem cells. Cardiovasc Res 2012;95:419–29. https://doi.org/10.1093/cvr/cvs206; PMID: 22799119.
12. Ma O, Wei H, Lu J, et al. Characterization of a novel KCNQ1 mutation for type 1 long QT syndrome and assessment of the therapeutic potential of a novel IKs activator using patient-specific induced pluripotent stem cell-derived cardiomyocytes. Stem Cell Res Ther 2015;6:39. https://doi.org/10.1186/s13287-015-0027-z; PMID: 25688901.
13. Izatkh I, Maiwall L, Huber I, et al. Modelling the long QT syndrome with induced pluripotent stem cells. Nature 2011;471:225–9. https://doi.org/10.1038/nature09747; PMID: 21402620.
14. Lathii A, Kujala VI, Chapman H, et al. Model for long QT syndrome type 2 using human iPSCs demonstrates arrhythmogenic characteristics in cell culture. Dis Model Mech 2012;5:230–30. https://doi.org/10.1242/dmm.008409; PMID: 22052944.
15. Matsa E, Dixon JE, Medway C, et al. Allele-specific RNA interference recues the long-QT syndrome phenotype in human-induced pluripotency stem cell cardiomyocytes. Eur Heart J 2014;35:1378–87. https://doi.org/10.1093/eurheartj/
Jung CB, Moretti A, Mederos y Schnitzler M, et al. Dantrolene corrects the transient outward K+ current in human induced pluripotent stem cell-derived cardiomyocytes. J Mol Cell Cardiol 2012;51:557-68. https://doi.org/10.1016/j.yjmcc.2012.07.010

Kim J, Lee J, Lim H, et al. High purity human-induced pluripotent stem cell pairs reveal the role of a KCNH2 mutation in long-QT syndrome. PLoS One 2012;7:e44660. https://doi.org/10.1371/journal.pone.0044660

Yamamoto Y, Mikami T, Harita T, et al. Alkyl-specific albinism rescues electrophysiological abnormalities in a human iPSC model of long-QT syndrome with a CALM2 mutation. Hum Mol Genet 2013;22:3833-42. https://doi.org/10.1093/hmg/ddt283

Bellin M, Casini S, Davis RP, et al. Isogenic human pluripotent stem cells recapitulate the disease-specific contractile phenotype of cardiac tissue models: a perspective from a research-based pharmaceutical company. Cold Spring Harb Perspect Biol 2017;18:571–82. https://doi.org/10.1101/cshperspect.a014092

Grom G, Mann I, Fitzgerald ID. Cardiovascular drug discovery: a perspective from a research-based pharmaceutical company. Cold Spring Harb Perspect Biol 2014;6:a014902. https://doi.org/10.1101/cshperspect.a014902

Ritter JM. Cardiac safety, drug-induced QT prolongation and torsade de pointes (TdP), Br J Clin Pharmacol 2012;73:331-4. https://doi.org/10.1111/j.1365-2125.2012.04193.x

Bellin M, Casini S, Davis RP, et al. Isogenic human pluripotent stem cells recapitulate the role of a KCNH2 mutation in long-QT syndrome. EMBO J 2013;32:3161-75. https://doi.org/10.1002/ebcm.20134.242152044

Dobrian ML, Diaz-Diaz L, et al. Maximum diastolic potential of human induced pluripotent stem cell derived cardiomyocytes depends critically on Ih. PLoS One 2018;13:e0199927. https://doi.org/10.1371/journal.pone.0199927

Huang HP, Chen PH, Hsu WL, et al. Human Pompe disease-induced pluripotent stem cells for pathogenesis modeling, drug testing and disease marker identification. Hum Mol Genet 2011;20:4851-64. https://doi.org/10.1093/hmg/ddr242

Yan L, Lee AS, Liang P, et al. Abnormal cardiac handling properties under fetal hypoxic cardiomyopathy pathophysiology in human induced pluripotent stem cells. Cell Stem Cell 2013;12:103-13. https://doi.org/10.1016/j.stem.2012.10.010

Lee YK, Loy VM, et al. Antidepressant treatment response for lamin A/C related diastolic cardiomyopathy in human induced pluripotent stem cells. J Am Heart Assoc 2017;6:e007657. https://doi.org/10.1161/JAHA.116.007657

Siu CW, Lee YK, Ho J, et al. Modeling of lamin A/C mutation premature cardiac aging using patient-specific induced pluripotent stem cells. Cell 2013;153:830-42. https://doi.org/10.1016/j.cell.2013.05.014

Caspi G, Huber I, Geppert A, et al. Modeling of arrhythmogenic right ventricular dysplasia with patient-specific iPSCs. Nature 2013;494:105-10. https://doi.org/10.1038/nature11797

Ma J, Wei H, Li, et al. Generation of patient-specific induced pluripotent stem cell-derived cardiomyocytes as a cellular model of lamin A/C cardio-myopathy. Eur Heart J 2013;34:1122-33. https://doi.org/10.1093/eurheartj/eut226; PMID: 22769862

Corrado M, Nesterenko L, et al. Identification and characterization of a transient outward K+ current in human induced pluripotent stem cell-derived cardiomyocytes. J Mol Cell Cardiol 2013;60:92-102. https://doi.org/10.1016/j.yjmcc.2013.03.014

Sobol R, Davis S, Møller GE, et al. Region and cell-type resolved quantitative protein expression. Nat Commun 2017;8:1469. https://doi.org/10.1038/s41467-017-0174-2; PMID: 29133944

Arai K, Arman M, Tatemoto V, Wu JC. Human induced pluripotent stem cell-derived cardiomyocytes: insights into cellular, molecular, and functional phenotypes. Circ Res 2015;117:88–90. https://doi.org/10.1161/CIRCRESAHA.114.309283

Fukuda T, Ahrens M, Roberts A, et al. Engineering autoimmunity: a perspective from a research-based pharmaceutical company. Cell Stem Cell 2014;14:511-23. https://doi.org/10.1016/j.stem.2014.08.017

Yan Y, Fabian L, Murray CE. Engineering autoimmunity: a perspective from a research-based pharmaceutical company. Cell Stem Cell 2014;14:511-23. https://doi.org/10.1016/j.stem.2014.08.017

Pröpper V, Steinmann PJ, et al. Improved generation, handling of human iPSC-derived cardiomyocytes generated by multiple laboratories. J Mol Cell Cardiol 2015;85:79-88. https://doi.org/10.1016/j.yjmcc.2015.03.059

Bajand N, Villac L, Oparil S, et al. Hypertrophic response to cardiac mechanical stress in undiseased human ventricular myocytes. Cardiovasc Res 1998;40:508-15. https://doi.org/10.1016/S0008-6363(98)00067-9
Dick E, Rajamohan D, Ronksley J, Denning C. Evaluating the use of cardiomyocytes from human induced pluripotent stem cells for drug screening. Biochem Soc Trans 2013;41:1037-45. https://doi.org/10.1042/BST0411037

Zhang XH, Haviland S, Wei H, et al. Calcium transients closely reflect prolonged action potentials in iPSC models of inherited cardiac arrhythmia. Stem Cell Rep 2014;3:269-81. https://doi.org/10.1016/j.stemcr.2014.06.003; PMID: 25254341.

Devalia HD, Gehan R, Abusuefi EH, et al. TECRL, a new life-threatening inherited arrhythmia gene associated with overlapping clinical features of both LQTS and CPVT. Circ Res 2013;112:549-61. https://doi.org/10.1161/CIRCRESAHA.111.249243; PMID: 23371903.

Okano H, Nakamura M, Yoshida K, et al. Steps toward safe cell therapy using induced pluripotent stem cells. Circ Res 2013;112:523-33. https://doi.org/10.1161/CIRCRESAHA.111.256149; PMID: 23371901.

Kawamura T, Suzuki I, Wang YV, et al. Linking the p53 tumour suppressor pathway to somatic cell reprogramming. Nature 2009;460:1140-4. https://doi.org/10.1038/nature08311; PMID: 19648186.

Gore A, Li Z, Fung H, et al. Somatic coding mutations in human induced pluripotent stem cells. Nature 2011;471:63-7. https://doi.org/10.1038/nature09805; PMID: 21368285.

Masumoto H, Kunz T, Takeda M, et al. Human iPS cell-engineered cardiac tissue sheets with cardiomyocytes and vascular cells for cardiac regeneration. Sci Rep 2014;4:6716. https://doi.org/10.1038/srep06716; PMID: 25334194.

Mills BJ, Parker BI, Quaiy-Ryan SA, et al. Drug screening in human PSC-cardiac organoids identifies pro-proliferative compounds acting via the mevalonate pathway. Cell Stem Cell 2019;24:895-907.e7. https://doi.org/10.1016/j.stem.2019.03.009; PMID: 30930147.

Saha K, Jaenisch R. Technical challenges in using human induced pluripotent stem cells to model disease. Cell Stem Cell 2009;5:384-95. https://doi.org/10.1016/j.stem.2009.11.009; PMID: 19951687.

de Almeida PE, Ransohoff RD, Nahid A, Wu J. Immunogenicity of pluripotent stem cells and their derivatives. Circ Res 2013;112:549-61. https://doi.org/10.1161/CIRCRESAHA.111.249243; PMID: 23371903.

One Health D, Spencer CI, Baba S, Nakamura K, et al. Calcium transients from normal and catecholaminergic polymorphic ventricular tachycardia (CPVT)-afflicted subjects. Circ Res 2013;112:549-61. https://doi.org/10.1161/CIRCRESAHA.111.249243; PMID: 23371903.

Saha K, Jaenisch R. Technical challenges in using human induced pluripotent stem cells to model disease. Cell Stem Cell 2009;5:384-95. https://doi.org/10.1016/j.stem.2009.11.009; PMID: 19951687.